Total Testosterone Test: Ranges, High and Low Results, Timing and What It Means

Most circulating testosterone is bound to SHBG or albumin; only a small fraction is free. Total testosterone adds those fractions together. It does not directly show how much hormone reaches every tissue or how strongly an androgen receptor responds.^{See reference 1,See reference 3,See reference 4}

Total testosterone is usually the first biochemical test in a male hypogonadism assessment. In women with possible androgen excess, total and free testosterone may be assessed alongside symptoms, menstrual or menopause context, medicines and other androgens.^{See reference 1,See reference 4,See reference 5}

A blood result does not identify the cause. Timing, sleep, food, illness, assay method, SHBG, prescribed hormones, anabolic steroids and some supplements can change the number or its interpretation.^{See reference 1,See reference 2,See reference 3,See reference 4,See reference 12}

Multiply ng/dL by 0.034671 to obtain nmol/L; multiply nmol/L by 28.842 to obtain ng/dL. For example, 300 ng/dL is about 10.40 nmol/L. The tools round only the displayed answer.^{See reference 13}

Keep the original result, unit, laboratory interval and assay together. Conversion cannot correct an assay difference or turn a guideline cut-point into a universal reference range.^{See reference 1,See reference 6}

Classify a boundary using the original laboratory value, not a rounded converted display. This converter runs locally in the browser and does not diagnose, store a result or recommend treatment.

Testosterone is diurnal and pulsatile, and a single result can be lowered by poor sleep, food, acute illness, undernutrition, intense exercise or medicines. Repeating a properly collected early-morning sample reduces the chance of labelling a temporary change as persistent deficiency.^{See reference 1,See reference 2,See reference 3}

Male hypogonadism is a clinical diagnosis: compatible symptoms or signs plus unequivocally and consistently low accurate testosterone, followed by evaluation of the cause. Routine screening of men without a clinical reason is not recommended by the Endocrine Society.^{See reference 1,See reference 7}

Do not delay urgent assessment for severe symptoms just to repeat a routine test. The repeat rule is about diagnostic accuracy, not a reason to ignore acute illness or neurologic warning signs.^{See reference 1}

Liquid chromatography–tandem mass spectrometry (LC-MS/MS) is the most specific approach and is preferred when concentrations are low, particularly in women and children. Automated immunoassays may perform acceptably in parts of the adult male range but can disagree across manufacturers or be biased at low values.^{See reference 1,See reference 4,See reference 5,See reference 6}

CDC’s hormone standardisation programme uses high-performance liquid chromatography with tandem mass spectrometry as a reference method and certifies specific method, reagent, instrument and time combinations. Certification improves comparability; it does not make every assay or laboratory interval interchangeable.^{See reference 6}

If a result is surprising or does not fit symptoms, repeat it under valid conditions and ask about the method. High-dose biotin can interfere with some laboratory immunoassays, so disclose supplements and follow the laboratory’s instructions.^{See reference 4,See reference 6,See reference 12}

Sleep, energy balance, weight-related metabolic health, alcohol, medicines and treatment of an underlying pituitary, testicular or systemic problem can change testosterone. The appropriate action depends on the cause; a lifestyle change is not a guaranteed way to correct structural hypogonadism.^{See reference 1,See reference 3}

Testosterone therapy is for appropriately diagnosed hypogonadism after symptoms, repeated accurate testing, cause, fertility, benefits, contraindications and monitoring are discussed. It is not a general anti-ageing, energy, weight-loss, muscle-building or longevity treatment.^{See reference 1,See reference 7}

TRAVERSE enrolled 5,246 men aged 45–80 with symptoms, cardiovascular disease or risk and two fasting testosterone values below 300 ng/dL. Testosterone gel was noninferior to placebo for major cardiovascular events over the trial period, but atrial fibrillation, acute kidney injury and pulmonary embolism occurred more often. The result does not establish safety for women, younger people, bodybuilding doses, every formulation or indefinite use.^{See reference 9}

FDA removed boxed-warning language about increased cardiovascular outcomes after reviewing TRAVERSE but requires class-wide blood-pressure warnings and retains a limitation for age-related hypogonadism. This is not a declaration that testosterone is risk-free.^{See reference 8}